For many cancer patients, immunotherapy offers a powerful fresh weapon in the fight against the disease. But this treatment, which harnesses the body’s own immune system, isn’t without its challenges. Increasingly, doctors are seeing immune-related adverse events – side effects caused by the immune system attacking healthy tissues – and one of the most debilitating is arthritis. Now, a new clinical trial in the UK is investigating whether an existing arthritis treatment can alleviate these symptoms and improve the quality of life for cancer patients undergoing immunotherapy.
The trial, known as REACT, focuses on patients experiencing arthritis triggered by immune checkpoint inhibitors (ICIs), a common type of immunotherapy. Researchers are comparing the effectiveness of standard steroid treatment with adalimumab, an anti-TNF drug often used to manage rheumatoid arthritis and other inflammatory conditions. This research addresses a critical need for better management of ICI-induced arthritis, a condition that can significantly disrupt cancer treatment and severely impact a patient’s well-being.
Rebecca Smith, 53, from Solihull, knows firsthand the devastating impact of this side effect. Diagnosed with eye cancer in early 2020, she initially responded well to treatment. However, when the cancer spread to her liver, she began immunotherapy. “I started immunotherapy last year, and although it offered hope, the side effects were brutal,” Smith explains. “I developed colitis, meningitis, and severe arthritis that attacked 90% of my joints. I couldn’t climb stairs, get dressed, or even get out of bed without help. It was devastating.”
Smith’s experience highlights the difficult trade-off many cancer patients face: the potential benefits of immunotherapy weighed against the often-severe side effects. Standard steroid therapy, while commonly used to manage inflammation, often provides limited relief and can interfere with the effectiveness of the immunotherapy itself. “Every cycle of treatment left me in hospital with side effects. It was a vicious circle,” Smith recalls. She was forced to take a year off operate due to the debilitating pain and fatigue.
A New Approach to Managing Immunotherapy Side Effects
When her consultant suggested the REACT trial, Smith eagerly enrolled. The trial, funded with more than £1 million from the National Institute for Health and Care Research (NIHR), aims to recruit 70 patients with ICI-induced arthritis across multiple centers in the UK. Participants are randomly assigned to receive either standard care – initial treatment with prednisolone, a type of steroid – or adalimumab injections every two weeks. The research is supported by the NIHR UK Musculoskeletal Translational Research Collaboration and the NIHR/Wellcome Trust Birmingham Clinical Research Facility.
For Smith, the results have been transformative. “It’s been a godsend,” she says. “My pain has eased, I can walk, I’ve returned to work, I can even wear heels again! My quality of life is back to what it was before.” While she still experiences mild aches before her next dose, the improvement has been dramatic. She shares her journey on Instagram (@one_eye_survivor_living_life) to inspire others facing similar challenges.
The trial isn’t just about symptom relief; it’s about optimizing cancer treatment. Researchers will monitor participants for up to a year, comparing arthritis activity, quality of life, the amount of immunosuppressive drugs needed, the number of missed immunotherapy doses, new immune-related side effects, cancer outcomes, and overall survival. Treatments will be adjusted as needed to control arthritis symptoms, with the goal of minimizing steroid leverage.
Looking Ahead: Improving Cancer Care Through Collaborative Research
The REACT trial is being conducted at the University of Birmingham’s Cancer Research UK Clinical Trials Unit (CRCTU), a globally recognized center for innovative research in both cancer and inflammatory diseases. The trial is scheduled to run until August 2028. The findings from this study could significantly impact how immunotherapy-related arthritis is managed, potentially allowing more patients to continue their cancer treatment without debilitating side effects.
As Smith emphasizes, trials like REACT offer more than just potential medical benefits. “Trials like this give people hope – and that’s priceless,” she says. “Don’t lose hope. Cancer and its side effects aren’t the finish of the world. If you get the chance to join a trial, take it. It might change your life – it’s certainly changed mine.”
The results of the REACT trial are eagerly anticipated by the medical community and cancer patients alike. Further research will be crucial to refine treatment strategies and personalize care for individuals experiencing immune-related adverse events during cancer immunotherapy.
Disclaimer: This article provides informational content and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your thoughts on the challenges of immunotherapy side effects? Share your experiences and perspectives in the comments below.
